Join us on the latest episode! Our Guest: Nicole K. Paulk, CEO & Founder at Siren Biotechnology.

What you'll get out of this episode:

• Nicole Paulk's early inspiration in gene therapy during her PhD at OHSU.
• The transition from academia to entrepreneurship amid COVID-19.
• Siren Biotechnology's innovative approach with AAV immunogene therapy.
• The challenges and successes in securing funding and navigating regulatory landscapes.
• The exciting transition of Siren Biotechnology from preclinical to clinical trials.

To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/nicolepaulk/
Company LinkedIn https://www.linkedin.com/company/siren-biotechnology-inc/
Website https://sirenbiotechnology.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Sam Cooper, Co-Founder & CTO at Phenomic.

What you'll get out of this episode:

• Sam Cooper shares his journey from Imperial College London to founding Phenomic.
• Phenomic's innovative approach combines AI with biological research.
• The company focuses on developing drugs targeting the tumor stroma.
• Phenomic's partnership with TileDB and Boehringer Ingelheim.
• Advice for budding biotech entrepreneurs from Sam Cooper.

To Learn More About Our Guests and their Companies:
LinkedIn https://www.linkedin.com/in/sam-cooper-537814134/
Company LinkedIn https://www.linkedin.com/company/phenomic/
Website https://phenomic.ai/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guests: Christine Senn, PhD, the SVP of Site-Sponsor Innovation at Advarra & Rohit Nambisan, Co-Founder and CEO at Lokavant.

What you'll get out of this episode:

• Rohit Nambisan discusses Lokavant's approach to leveraging AI in clinical trial feasibility.
• Christine Senn highlights the importance of thorough feasibility processes in rare disease trials.
• The need for diverse site participation and data inputs to improve trial accuracy and efficiency.
• The role of AI and technology in enhancing clinical trial processes.

To learn more about our guests and their companies:
Christine's LinkedIn https://www.linkedin.com/in/christinesenn/
Rohit's LinkedIn https://www.linkedin.com/in/rohitnambisan/

Advarra LinkedIn https://www.linkedin.com/company/advarra/
Lokavant LinkedIn https://www.linkedin.com/company/lokavant/

Advarra Website https://www.advarra.com/
Lokavant Website https://www.lokavant.com/en-us/

Our sponsor for this episode is:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Dr. Sam Clark, Founder and CEO at Terran Biosciences.

What you'll get out of this episode:

• Revolutionizing Treatments: Dr. Sam Clark discusses Terran Biosciences' mission to innovate treatments for neurological and psychiatric conditions.
• Innovative Drug Development: The company focuses on creating new mechanisms for treating depression, bipolar disorder, and schizophrenia.
• Smaller, Agile Teams: Terran Biosciences operates with a flat structure, utilizing highly trained experts to solve complex problems.
• Addressing Patent Monopolies: The company aims to break patent monopolies in pharma through innovative approaches and pro-drug strategies.
• Exciting Developments: Dr. Clark teases upcoming announcements, including long-acting and improved drug forms.

To learn more about our guests and their companies:
LinkedIn https://www.linkedin.com/in/sam-clark-md-phd-133139199/
Company LinkedIn https://www.linkedin.com/company/terran/
Website https://terranbiosciences.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Dr. Michael Kyle, SVP & Chief Medical Officer at Currax Pharmaceuticals.

What you'll get out of this episode:

• Dr. Michael Kyle's Background: Insights into his journey from medical practice to becoming SVP & Chief Medical Officer of Currax Pharmaceuticals.
• Understanding Obesity: A discussion on different types of obesity and the importance of tailored treatments.
• Global Perspectives: Comparing how the U.S. and European countries handle obesity and the lessons to be learned.
• Evolving Treatments: The parallel evolution of hypertension and obesity treatments.
• Behavioral Approaches: The importance of sustainable lifestyle changes and behavior modification in addressing obesity.

To learn more about our guests and their companies:
LinkedIn https://www.linkedin.com/in/michael-l-kyle/
Company LinkedIn https://www.linkedin.com/company/currax-pharmaceuticals-llc/
Website https://www.curraxpharma.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Colin Weller, VP & GM of Evidence Platform at Medable.

What you'll get out of this episode:

• Introduction of Colin Weller: Vice President and GM of Evidence Platform at Medable, Colin Weller discusses his role in advancing clinical research technology to streamline drug approvals.
• Challenges in Drug Development: Weller details the stagnant pace of drug development, highlighting the industry's need for innovation to improve efficiency and reduce costs.
• Medable's Ambitious Goals: Aiming to increase the number of drugs approved annually by tenfold through advanced SAS technology and AI, setting a new industry standard.
• Innovations in Clinical Trials: Medable has already cut study startup times by 50%, utilizing AI and automation to overhaul traditional processes.
• Future of Digital Clinical Trials: Weller predicts significant advancements in decentralized and digital trials, enhancing patient accessibility and data quality.

To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/colin-weller-294ab58/
Company LinkedIn: https://www.linkedin.com/company/medable-inc-/
Website: https://www.medable.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Stella K. Vnook, CEO at Likarda.

What you'll get out of this episode:

• Stella Vnook, CEO of Likarda, discusses her transition from a science background to the business side of biotech and her journey to becoming CEO.
• Likarda specializes in core-shell spherification, creating beads with cells for targeted drug delivery, improving viability and efficacy.
• The company aims to enhance cell therapies, especially in liver cells and hormone therapy, and simplify cell transport logistics.
• Likarda's future goals include launching off-the-shelf products for osteoarthritis and advancing partnerships in cell therapy and regenerative medicine.
• Funding strategies and future plans involve a Series A funding round, non-dilutive funding, and efficient use of resources to scale up and innovate.

To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/vnook/
Company LinkedIn: https://www.linkedin.com/company/likarda-llc/
Website: https://likarda.com/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Samantha Dale Strasser, CEO & Co-Founder at Pepper Bio.

What you'll get out of this episode:

• Samantha Dale Strasser, co-founder and Chief Science Officer of Pepper Bio, shares her transition from academia to entrepreneurship, driven by a personal mission to change healthcare outcomes.
• Pepper Bio, located in Boston, leverages transomics to integrate multiple data sets for precision medicine, aiming to treat diseases that are currently untreatable.
• Strasser’s focus is on developing treatments for challenging diseases, with an emphasis on oncology, inflammatory diseases, and neurodegenerative disorders.
• Pepper Bio’s approach in drug discovery combines its own pipeline development with strategic partnerships, speeding up the process of bringing new treatments to the clinic.
• The company has made significant strides in identifying novel targets and shelved assets, leading to a high success rate in in vivo model validations.

To learn more about our guests and their companies:
LinkedIn: https://www.linkedin.com/in/samantha-dale-strasser/
Company LinkedIn: https://www.linkedin.com/company/pepperbio/
Website: https://pepper.bio/

Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/

BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/